CAM
CRVS icon

Cormorant Asset Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Cormorant Asset Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-81,000
Closed -$1.68M – 74
2017
Q1 		$1.68M Sell
81,000
-117,526
-59% -$1.84M 0.24% 64
2016
Q4 		$2.84M Sell
198,526
-15,606
-7% -$237K 0.38% 53
2016
Q3 		$3.52M Hold
214,132
– – 0.39% 60
2016
Q2 		$3.05M Buy
+214,132
New +$2.89M 0.43% 54

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cormorant Asset Management's CRVS Position: Q2 2017 in Review

Cormorant Asset Management sold out of Corvus Pharmaceuticals (CRVS) in Q2 2017, closing a stake of 81,000 shares — an estimated $1.68M sold.

Cormorant Asset Management first reported a position in CRVS in Q2 2016 and held it in 4 quarters. The position peaked at $3.52M in Q3 2016. 52 funds tracked by Wall St. Rank hold CRVS as of Q2 2017.

  • Cormorant Asset Management reported no remaining Corvus Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Cormorant Asset Management sold 81,000 Corvus Pharmaceuticals shares in Q2 2017, an estimated $1.68M.
  • Cormorant Asset Management first reported a position in Corvus Pharmaceuticals in Q2 2016 and held it in 4 quarters.
  • Cormorant Asset Management's Corvus Pharmaceuticals position peaked at $3.52M in Q3 2016.
  • 52 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2017.

Based on Cormorant Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.